Browsing Tag
Exact Sciences
5 posts
Abbott (ABT) stock surges 12% as Q2 earnings beat lifts 2026 EPS outlook to $5.45-$5.60
Abbott shares headed for their strongest daily gain in 24 years after the healthcare group beat second-quarter expectations and raised its adjusted earnings forecast.
What does Abbott’s Cancerguard AACR data mean for multi-cancer early detection and the $21bn Exact Sciences acquisition?
Abbott presents Cancerguard dual-biomarker MCED data at AACR 2026. What the DETECT-A survival findings mean for ABT, GRAIL, and cancer screening. Read more.
Abbott (ABT) closes $21bn Exact Sciences deal, making it the leader in U.S. cancer screening diagnostics
Abbott (ABT) closes its $21bn Exact Sciences acquisition, creating a $12bn+ diagnostics leader in cancer screening and precision oncology. Read the full analysis.
Can Freenome’s $1.1bn SPAC deal unlock a new chapter for blood-based multi-cancer detection?
Freenome merges with PCSC in $1.1B deal to go public as FRNM. Find out how its AI-powered blood tests could change early cancer detection.
Exact Sciences to acquire Thrive Earlier Detection in landmark $2.15bn deal
In a move set to revolutionize cancer detection, Exact Sciences, a prominent US molecular diagnostics company, has announced…